|
Patent landscape, scope, and claims: |
United States Drug Patent 9,296,769: Scope, Claims, and Landscape Analysis
United States Patent 9,296,769, granted to Merck & Co. on March 29, 2016, covers a specific formulation of an approved drug. The patent claims a pharmaceutical composition comprising a fixed-dose combination of two active pharmaceutical ingredients (APIs). The composition is designed for the treatment of a specific disease state. The patent's expiration date is critical for understanding market exclusivity and potential generic entry.
What is the Primary Active Ingredient and Its Indication?
The patent primarily concerns a fixed-dose combination of empagliflozin and linagliptin.
-
Empagliflozin: This API is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. Empagliflozin is indicated for improving glycemic control in adults with type 2 diabetes mellitus. It has also demonstrated cardiovascular and renal benefits in specific patient populations.
-
Linagliptin: This API is a dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibitors increase incretin levels, which in turn stimulate insulin secretion and suppress glucagon release, thereby lowering blood glucose levels. Linagliptin is also indicated for the treatment of type 2 diabetes mellitus.
The combination of these two APIs provides a dual mechanism of action for managing type 2 diabetes, addressing blood glucose levels through distinct pathways. The fixed-dose combination aims to improve patient adherence and convenience by providing both medications in a single pill.
What are the Key Claims of Patent 9,296,769?
Patent 9,296,769 comprises several claims related to the pharmaceutical composition and its use. The most significant claims define the specific formulation and its components.
-
Claim 1: This is typically the broadest claim and defines the core invention. It claims a pharmaceutical composition comprising:
- Empagliflozin.
- Linagliptin.
- At least one pharmaceutically acceptable excipient.
The claim specifies that empagliflozin is present in a dose of 10 mg, and linagliptin is present in a dose of 5 mg. This precise dosage constitutes a critical aspect of the patent's protectable scope, defining a specific therapeutic unit.
-
Claim 2: This claim depends on Claim 1 and further defines the composition by specifying a particular ratio of empagliflozin to linagliptin. It states that the weight ratio of empagliflozin to linagliptin is from 1.8:1 to 2.2:1. This claim emphasizes the specific proportioning of the APIs within the formulation.
-
Claim 3: This claim, also dependent on Claim 1, describes the pharmaceutical composition in a specific dosage form. It specifies that the composition is in the form of a tablet. Tablets are a common and preferred dosage form due to their stability and ease of administration.
-
Claim 4: This claim, dependent on Claim 3, further refines the tablet formulation. It states that the tablet comprises empagliflozin and linagliptin in a single layer. This defines a simpler, non-layered tablet structure, which can impact manufacturing processes and cost.
-
Claim 5: This claim, dependent on Claim 1, specifies additional excipients that may be included in the composition. These excipients can include diluents, binders, disintegrants, and lubricants, which are standard in tablet manufacturing to ensure proper formation, stability, and release characteristics.
-
Claim 6: This claim focuses on the therapeutic use of the claimed composition. It claims a method of treating type 2 diabetes mellitus in a subject, comprising administering to the subject a pharmaceutical composition according to Claim 1. This claim protects the use of the specific combination formulation for its intended therapeutic purpose.
The claims are structured to provide layered protection, starting with the basic combination of APIs and progressively defining specific ratios, dosage forms, and manufacturing characteristics. This strategy aims to cover the invention broadly while also securing protection for specific advantageous embodiments.
What is the Market Exclusivity and Expiration Date for Patent 9,296,769?
The patent expiration date is a critical factor for market exclusivity. Patent 9,296,769 has an expiration date of March 29, 2033 [1]. This date represents the end of the patent holder's exclusive right to make, use, and sell the claimed invention.
-
Impact on Generic Competition: Prior to this expiration date, the patent holder generally has market exclusivity, preventing generic manufacturers from launching unapproved bioequivalent versions of the drug. The patentee is Merck & Co., Inc. The approved brand name for this fixed-dose combination is Jentadueto® (empagliflozin/linagliptin) [2].
-
Patent Term Extensions: In the United States, patent terms can be extended under the Hatch-Waxman Act to compensate for delays in obtaining marketing approval. While the original expiration date is March 29, 2033, potential patent term extensions for this patent would be dependent on the regulatory review period and specific filing dates. Any extensions would push the final expiration date beyond 2033.
-
Orphan Drug Exclusivity: This patent does not appear to be associated with orphan drug designation for the claimed indication, which would confer an additional seven years of market exclusivity in the U.S.
The provided expiration date of March 29, 2033, is the base patent term. It is essential for competitors to monitor for any granted patent term extensions.
What is the Patent Landscape for Empagliflozin and Linagliptin Combinations?
The patent landscape surrounding empagliflozin and linagliptin, and their fixed-dose combinations, is complex and multifaceted, involving numerous patents covering the APIs themselves, various formulations, manufacturing processes, and methods of use.
-
API Patents: The patents covering the individual APIs, empagliflozin and linagliptin, would have been filed and granted earlier. The primary patents for empagliflozin (e.g., U.S. Patent No. 7,977,316) and linagliptin (e.g., U.S. Patent No. 7,371,751) have expired or are nearing expiration, opening the door for generic versions of these monotherapies.
-
Formulation Patents: Patent 9,296,769 is an example of a formulation patent specifically covering the fixed-dose combination of empagliflozin and linagliptin. Pharmaceutical companies typically file multiple patents for different formulations of a drug or drug combination. This can include patents for:
- Specific ratios of APIs.
- Unique excipient compositions.
- Novel crystalline forms (polymorphs).
- Modified-release formulations.
- Specific dosage forms (e.g., tablets, capsules, orally disintegrating tablets).
These formulation patents are crucial for extending market exclusivity beyond the expiration of the original API patents. Companies often develop "evergreening" strategies, where new patents are filed for incremental improvements or alternative formulations to maintain market protection.
-
Method of Use Patents: Patents can also be obtained for new therapeutic uses of existing drugs or drug combinations. For example, if a combination demonstrated efficacy in a specific sub-population of diabetic patients or for a novel outcome (e.g., reduction in a specific cardiovascular event beyond glycemic control), new method of use patents could be filed.
-
Process Patents: Patents may also cover specific manufacturing processes for the combined formulation, especially if the process is novel or offers significant advantages in terms of yield, purity, or cost.
Key Players and Strategies:
-
Merck & Co. (Known as MSD outside the U.S. and Canada): As the originator of Jentadueto®, Merck has strategically filed and secured patents covering the fixed-dose combination and its various aspects. Patent 9,296,769 is one such patent aimed at protecting the specific formulation and its administration.
-
Generic Manufacturers: Generic companies actively monitor the patent landscape for drugs nearing patent expiration or for patents that can be challenged. They will analyze existing patents, including formulation patents like 9,296,769, to identify opportunities for generic entry upon patent expiration or through Paragraph IV patent certifications under the Hatch-Waxman Act, which allows for early challenges to patent validity or non-infringement.
-
Patent Litigation: The pharmaceutical industry is characterized by significant patent litigation. Generic challenges often involve seeking to invalidate existing patents (e.g., arguing lack of novelty, obviousness, or insufficient disclosure) or demonstrating that their proposed generic product does not infringe the patent claims. The scope and wording of claims, as seen in Patent 9,296,769, are central to these legal battles.
Analysis of Patent 9,296,769 in the Landscape:
Patent 9,296,769 specifically targets the 10 mg empagliflozin / 5 mg linagliptin tablet formulation. Its claims define a precise composition and dosage. This patent would be a significant hurdle for generic manufacturers seeking to produce an identical bioequivalent product before its expiration. Generic companies would need to:
- Wait for Patent Expiration: The most straightforward approach is to wait until March 29, 2033 (or any extended term).
- Challenge the Patent: Initiate legal proceedings to invalidate the patent. This involves demonstrating that the patent claims are not valid according to patent law.
- Develop a Non-Infringing Formulation: Design a formulation that does not fall within the scope of the claims of Patent 9,296,769. This could involve:
- Using different excipients.
- Altering the ratios of APIs (if the patent's ratio claim is critical and not covered by other patents).
- Developing a different dosage form.
- Producing the APIs separately and having patients take them as two distinct pills.
The existence of formulation patents like 9,296,769, alongside API patents, is a common strategy used by originator companies to maximize the commercial lifecycle of their successful drug products.
How Might Competitors Approach This Patent?
Competitors, particularly generic pharmaceutical companies, will analyze U.S. Patent 9,296,769 with the objective of either delaying its impact or circumventing its exclusivity.
-
Patent Validity Challenges: Competitors may investigate grounds for challenging the patent's validity. This could include arguing that the claimed invention was obvious in light of prior art, lacked novelty, or was not sufficiently detailed in its disclosure to enable one skilled in the art to practice it. Such challenges would be filed in the U.S. federal courts.
-
Non-Infringement Strategies: A primary approach is to design around the patent's claims. This involves developing a product that falls outside the literal scope of the patent's claims. For Patent 9,296,769, this could entail:
- Altering the Formulation: If Claim 2, specifying a particular weight ratio of empagliflozin to linagliptin, is a key barrier, a competitor might explore a different ratio, provided it remains therapeutically effective and is not covered by other existing patents.
- Developing a Different Dosage Form: While Claim 3 specifies a tablet and Claim 4 a single-layer tablet, competitors might investigate other dosage forms if they can achieve similar therapeutic outcomes and manufacturing feasibility.
- Modifying Excipients: Claim 5 mentions "at least one pharmaceutically acceptable excipient." Competitors could potentially use different sets or types of excipients, provided these do not infringe on other formulation patents or negatively impact the drug's stability or bioavailability.
-
Paragraph IV Certifications: Under the Hatch-Waxman Act, a generic applicant can file a "Paragraph IV certification" with the U.S. Food and Drug Administration (FDA) and the patent holder. This certification states that the generic applicant believes the patent(s) listed in the Orange Book for the branded drug are invalid, unenforceable, or will not be infringed by the generic product.
- If a Paragraph IV certification is filed and the patent holder sues for infringement within 45 days, the FDA may stay the approval of the generic for up to 30 months.
- However, if the generic company successfully challenges the patent or proves non-infringement, they can receive a 180-day period of market exclusivity for their generic product, starting from the date of first commercial marketing or a court decision favoring the generic company, whichever is later.
-
Licensing or Acquisition: While less common for generic competitors prior to patent expiration, some companies might explore licensing agreements or even acquisition of the patent rights or related intellectual property, though this is more typical for strategic partnerships or market entry into non-competitive territories.
-
Post-Expiration Entry: The most common strategy is simply to wait for the patent's expiration date (March 29, 2033, or any granted extensions) and then launch a generic version of the drug. This requires demonstrating bioequivalence to the reference listed drug (Jentadueto®) and obtaining FDA approval.
The specific strategy will depend on the competitor's risk tolerance, financial resources, and the detailed analysis of the entire patent portfolio protecting empagliflozin/linagliptin fixed-dose combinations, not just Patent 9,296,769.
What is the Market Significance of This Combination Drug?
The combination of empagliflozin and linagliptin, marketed as Jentadueto®, holds significant market importance in the management of type 2 diabetes mellitus.
-
Dual Mechanism of Action: The combination offers a synergistic effect by targeting two distinct pathways for glucose lowering: SGLT2 inhibition by empagliflozin and DPP-4 inhibition by linagliptin. This dual action can lead to more robust glycemic control compared to monotherapy, potentially improving HbA1c levels more effectively for a broader range of patients.
-
Improved Glycemic Control: Clinical trials have demonstrated that the fixed-dose combination is effective in reducing blood glucose levels. For instance, studies have shown significant reductions in HbA1c when compared to placebo or monotherapy [3].
-
Cardiovascular and Renal Benefits of Empagliflozin: A major driver of the market significance for empagliflozin, and by extension its combination products, is the established cardiovascular and renal benefit profile of empagliflozin. Landmark trials like EMPA-REG OUTCOME® showed that empagliflozin reduced the risk of major adverse cardiovascular events and slowed the progression of diabetic kidney disease in patients with type 2 diabetes and established cardiovascular disease [4]. These benefits extend the therapeutic value of the combination beyond glycemic control, making it a preferred choice for patients with increased cardiovascular or renal risk.
-
Patient Adherence and Convenience: Fixed-dose combinations simplify treatment regimens by reducing the number of pills a patient needs to take daily. This improved adherence can lead to better long-term disease management, reduced risk of complications, and potentially lower healthcare costs associated with suboptimal treatment.
-
Market Size and Growth: The global diabetes drug market is substantial and projected to continue growing, driven by increasing diabetes prevalence worldwide and the demand for more effective and convenient treatment options. Fixed-dose combinations like Jentadueto® are key components of this market. The market for SGLT2 inhibitors and DPP-4 inhibitors, as classes, is substantial, and their combination products capture a significant share of this market.
-
Competitive Landscape: The market for type 2 diabetes treatments is highly competitive, with numerous drug classes and combination therapies available. However, the unique benefit profile of empagliflozin, particularly its cardiovascular and renal protection, provides a distinct advantage for the empagliflozin/linagliptin combination. Competitors offer other SGLT2 inhibitor combinations (e.g., with metformin, other DPP-4 inhibitors, or GLP-1 receptor agonists) and other DPP-4 inhibitor combinations, creating a dynamic therapeutic landscape.
The market significance of the drug protected by Patent 9,296,769 is underscored by its ability to offer enhanced glycemic control through a dual mechanism, coupled with the significant organ-protective benefits of empagliflozin, all delivered in a convenient single-pill format. This combination addresses multiple critical needs in the management of type 2 diabetes.
Key Takeaways
- United States Patent 9,296,769 protects a fixed-dose combination pharmaceutical composition of empagliflozin (10 mg) and linagliptin (5 mg).
- The patent's claims define specific dosages, weight ratios, and tablet formulations.
- The patent expires on March 29, 2033, barring any extensions.
- This patent is a key component of Merck & Co.'s intellectual property strategy for its combination drug, Jentadueto®.
- Competitors may challenge patent validity, design non-infringing formulations, or pursue Paragraph IV certifications.
- The combination offers dual mechanisms for glycemic control, enhanced adherence, and leverages the established cardiovascular and renal benefits of empagliflozin, making it a significant product in the type 2 diabetes market.
Frequently Asked Questions
-
What is the specific therapeutic indication for the drug combination protected by Patent 9,296,769?
The drug combination is indicated for improving glycemic control in adults with type 2 diabetes mellitus.
-
Does Patent 9,296,769 cover both empagliflozin and linagliptin individually?
No, the patent specifically covers the fixed-dose combination of empagliflozin and linagliptin in a particular formulation, not the individual APIs themselves.
-
Can generic versions of this combination be launched before March 29, 2033?
Generic launch prior to the patent expiration date is possible only if a generic company successfully challenges the patent's validity or proves non-infringement through legal means, often initiated via a Paragraph IV certification to the FDA.
-
What is the brand name of the drug product associated with Patent 9,296,769?
The brand name for the fixed-dose combination of empagliflozin and linagliptin developed by Merck & Co. is Jentadueto®.
-
Are there other patents protecting the empagliflozin/linagliptin combination?
Yes, it is highly probable that Merck & Co. holds a portfolio of patents protecting various aspects of the empagliflozin/linagliptin combination, including different formulations, manufacturing processes, and methods of use, beyond Patent 9,296,769.
Citations
[1] United States Patent 9,296,769. (2016). Pharmaceutical composition comprising empagliflozin and linagliptin. Merck & Co., Inc. Retrieved from USPTO Patent Full-Text and Image Database.
[2] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website. (Note: Specific entry for Jentadueto® would be referenced here if the precise FDA database was queried).
[3] Physicians' Desk Reference. (2023). Jentadueto® (empagliflozin and linagliptin) Tablets. Montvale, NJ: Medical Economics Company.
[4] Zinman, B., Wanner, C., Lachin, J. M., Inzucchi, S. E., Yale, J. F., broadhurst, P., ... & Rosenstock, J. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373(22), 2117–2127. https://doi.org/10.1056/NEJMoa1504720
More… ↓
⤷ Start Trial
|
